In particular, the use of novel screening techniques such as a semi-mechanistic pharmacokinetic/receptor occupancy (SM-PK/RO) model was used to identify anti-NKG2A mAbs with a high specific monovalent affinity for NKG2A and anti-tumor cytotoxicity [164]. Here, KLRC1 is linked to neoplasm.